Sarepta Therapeutics Inc (SRPT)

NASDAQ
Currency in USD
61.81
+2.32(+3.90%)
Closed·
After Hours
61.88+0.07(+0.11%)
·
SRPT Scorecard
Full Analysis
Net income is expected to grow this year
Earnings results expected in 5 days
Fair Value
Day's Range
58.7661.91
52 wk Range
48.01173.25
Key Statistics
Edit
Prev. Close
59.49
Open
59.63
Day's Range
58.76-61.91
52 wk Range
48.01-173.25
Volume
1.51M
Average Vol. (3m)
1.93M
1-Year Change
-49.21%
Book Value / Share
15.99
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SRPT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
147.33
Upside
+138.36%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period
Show more

Sarepta Therapeutics Inc Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children’s Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Employees
1372

Sarepta Therapeutics Inc SWOT Analysis


Future Horizons
Analyst targets range from $75 to $215, reflecting diverse views on Sarepta's potential for expansion into new indications and geographic markets
Market Dominance
Delve into Sarepta's leadership in the DMD market, leveraging extensive experience and relationships to maintain a competitive edge
Financial Prowess
Explore Sarepta's impressive financial performance, with Q3 revenues of $430 million and projections of up to $4.1 billion by 2026
Elevidys Triumph
Sarepta's gene therapy for DMD exceeds revenue expectations, driving substantial growth despite recent safety concerns and fierce market competition
Read full SWOT analysis

Compare SRPT to Peers and Sector

Metrics to compare
SRPT
Peers
Sector
Relationship
P/E Ratio
25.5x−2.5x−0.5x
PEG Ratio
0.18−0.090.00
Price / Book
3.9x1.5x2.6x
Price / LTM Sales
3.2x13.0x2.9x
Upside (Analyst Target)
161.3%134.6%57.2%
Fair Value Upside
Unlock4.9%8.9%Unlock

Analyst Ratings

21 Buy
4 Hold
0 Sell
Ratings:
25 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 147.33
(+138.36% Upside)

Earnings

Latest Release
Feb 26, 2025
EPS / Forecast
1.90 / 1.54
Revenue / Forecast
658.40M / 589.45M
EPS Revisions
Last 90 days

People Also Watch

267.89
APP
+6.16%
79.18
AKAM
+4.36%
492.27
VRTX
-0.03%
75.29
ANET
+6.40%
62.63
NVO
+2.17%

FAQ

What Is the Sarepta (SRPT) Stock Price Today?

The Sarepta stock price today is 61.81

What Stock Exchange Does Sarepta Trade On?

Sarepta is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Sarepta?

The stock symbol for Sarepta is "SRPT."

What Is the Sarepta Market Cap?

As of today, Sarepta market cap is 5.97B.

What is Sarepta Earnings Per Share?

The Sarepta EPS is 2.47.

What Is the Next Sarepta Earnings Date?

Sarepta will release its next earnings report on Apr 30, 2025.

From a Technical Analysis Perspective, Is SRPT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.